Thomas Lipscomb submitted an abstract titled "FUNCTION AND CLINICAL APPLICATION OF EMBRYONIC GENE NANOG IN CANCER" about the role of the embryonic gene Nanog in acute myeloid leukemia (AML). The study found that Nanog is expressed in AML cell lines and primary human AML cells. Decreasing Nanog expression in HL60 AML cells through sodium orthovanadate treatment decreased cell proliferation, as measured by trypan blue staining and real-time PCR. The results suggest Nanog may be a biomarker and therapeutic target for AML, and decreasing its expression could help treat the disease.
Intelligent Systems for Cancer Genomics (AIS305) - AWS re:Invent 2018Amazon Web Services
One of the most exciting frontiers in science is building automated systems that use existing biomedical data to understand and ultimately treat human disease. The key difficulty in the case of cancer is that it is a highly heterogeneous disease, making it challenging to uncover which molecular alterations in tumors are important for the disease and to predict how an individual will respond to treatment. This talk presents an overview of integrative computational methods for analyzing cancer genomes that leverage a diverse range of complementary data in order to extract biomedically relevant insights.
Intelligent Systems for Cancer Genomics (AIS305) - AWS re:Invent 2018Amazon Web Services
One of the most exciting frontiers in science is building automated systems that use existing biomedical data to understand and ultimately treat human disease. The key difficulty in the case of cancer is that it is a highly heterogeneous disease, making it challenging to uncover which molecular alterations in tumors are important for the disease and to predict how an individual will respond to treatment. This talk presents an overview of integrative computational methods for analyzing cancer genomes that leverage a diverse range of complementary data in order to extract biomedically relevant insights.
New definition and new theory (stem cell-microRNA Theory) of cancer-by dr.ra...Rajkumar Dhaugoda
Lecture notes on New definition and new theory (stem cell-microRNA Theory) of cancer
General concept of cancer
By Dr.Rkdhaugoda
CTGU, YICHANG CHINA-
Visiting Assistant professor ( FROM NEPAL)
2014- MAY-5th
Key achievements in cancer research at Cold Spring Harbor Laboratory: May 201...cshlnews
May is National Cancer Research Month. In recognition, here's a glimpse of key achievements in cancer research over the last 12 months (May 2010 - May 2011) at Cold Spring Harbor Laboratory, which has been an NCI-designated Cancer Center since 1987.
Cancer stem cell theory and evidence from colorecatalKareem Ahmed
This is a presentation of a review article explaining theory of cancer stem cells with evidences from colorectal cancer at a glance. It was presented at Student Research Symposium at Faculty OF Medicine, Assiut University, Assiut, Egypt,
New definition and new theory (stem cell-microRNA Theory) of cancer-by dr.ra...Rajkumar Dhaugoda
Lecture notes on New definition and new theory (stem cell-microRNA Theory) of cancer
General concept of cancer
By Dr.Rkdhaugoda
CTGU, YICHANG CHINA-
Visiting Assistant professor ( FROM NEPAL)
2014- MAY-5th
Key achievements in cancer research at Cold Spring Harbor Laboratory: May 201...cshlnews
May is National Cancer Research Month. In recognition, here's a glimpse of key achievements in cancer research over the last 12 months (May 2010 - May 2011) at Cold Spring Harbor Laboratory, which has been an NCI-designated Cancer Center since 1987.
Cancer stem cell theory and evidence from colorecatalKareem Ahmed
This is a presentation of a review article explaining theory of cancer stem cells with evidences from colorectal cancer at a glance. It was presented at Student Research Symposium at Faculty OF Medicine, Assiut University, Assiut, Egypt,
Christians Restored ! JÉSUS-CHRIST COMMAND ! Russian ! World War ! NUCLEAR WAR ! NOW ! GAZA ! ISRAËL ! CHINESE ! SURVIVAL ! RESTORED PURE CHRISTIAN CHURCH ! ANTICHRIST ! ISRAËL ! JÉSUS-CHRIST COMMAND BY PROPHET CHRISTIAN JEAN-JACQUES PUGIN ! WHO IS JEAN-JACQUES PUGIN ? JÉSUS COMMAND : SAYING YAHOUH (YHWH) ! That's the Name of God ! JÉSUS COMMAND : NOT EATING ANIMALS !
Zeine Seminar 2010, Cancer Associated Fibroblasts and Microvascular Prolifera...Rana ZEINE, MD, PhD, MBA
World Cancer Congress 2010
Presence of Cancer-Associated Fibroblasts correlates with Microvascular Proliferation which is a Poor Prognostic Factor in Neuroblastoma Tumors
https://www.medicalnewstoday.com/articles/323444.php
https://ascopubs.org/doi/full/10.1200/JCO.2008.16.0333
https://journals.lww.com/co-hematology/Abstract/2007/03000/Influence_of_new_molecular_prognostic_markers_in.5.aspx
Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances
Mrózek, Krzysztofa; Döhner, Hartmutb; Bloomfield, Clara Da
Current Opinion in Hematology: March 2007 - Volume 14 - Issue 2 - p 106–114
doi: 10.1097/MOH.0b013e32801684c7
Myeloid disease
Purpose of review Molecular study of cytogenetically normal acute myeloid leukemia is among the most active areas of leukemia research. Despite having the same normal karyotype, adults with de-novo cytogenetically normal acute myeloid leukemia who constitute the largest cytogenetic group of acute myeloid leukemia, are very diverse with respect to acquired gene mutations and gene expression changes. These genetic alterations affect clinical outcome and may assist in selection of proper treatment. Herein we critically summarize recent clinically relevant molecular genetic studies of cytogenetically normal acute myeloid leukemia.
Recent findings NPM1 gene mutations causing aberrant cytoplasmic localization of nucleophosmin have been demonstrated to be the most frequent submicroscopic alterations in cytogenetically normal acute myeloid leukemia and to confer improved prognosis, especially in patients without a concomitant FLT3 gene internal tandem duplication. Overexpressed BAALC, ERG and MN1 genes and expression of breast cancer resistance protein have been shown to confer poor prognosis. A gene-expression signature previously suggested to separate cytogenetically normal acute myeloid leukemia patients into prognostic subgroups has been validated on a different microarray platform, although gene-expression signature-based classifiers predicting outcome for individual patients with greater accuracy are still needed.
Summary The discovery of new prognostic markers has increased our understanding of leukemogenesis and may lead to improved prognostication and generation of novel risk-adapted therapies.
http://www.bloodjournal.org/content/127/1/53?sso-checked=true
An update of current treatments for adult acute myeloid leukemia
Hervé Dombret and Claude Gardin
Abstract
Recent advances in acute myeloid leukemia (AML) biology and its genetic landscape should ultimately lead to more subset-specific AML therapies, ideally tailored to each patient's disease. Although a growing number of distinct AML subsets have been increasingly characterized, patient management has remained disappointingly uniform. If one excludes acute promyelocytic leukemia, current AML management still relies largely on intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT), at least in younger patients who can tolerate such intensive treatments. Nevertheless, progress has been made, notably in terms of standard drug dose in ...
The role of traf3 and cyld mutationin the etiology of human papillomavirus dr...TÀI LIỆU NGÀNH MAY
Để xem full tài liệu Xin vui long liên hệ page để được hỗ trợ
: https://www.facebook.com/thuvienluanvan01
HOẶC
https://www.facebook.com/garmentspace/
https://www.facebook.com/thuvienluanvan01
https://www.facebook.com/thuvienluanvan01
tai lieu tong hop, thu vien luan van, luan van tong hop, do an chuyen nganh
Newer biomarkers,techniques & their inclusion in 2016 WHO classification for leukaemia/lymphomas increases the responsibility of the pathologists, requiring to develop an integrated multidisciplinary approach for reporting.
Robert Anders, MD, PhD, Robert L. Ferris, MD, PhD, and Lauren L. Ritterhouse, MD, PhD, prepared useful Practice Aids pertaining to biomarker testing for this CME/MOC activity titled "The Central Role of Biomarker Testing in Piecing Together the Immuno-Oncology Puzzle: Essential Guidance for Pathologists to Maximize the Potential of Cancer Immunotherapies." For the full presentation, monograph, complete CME/MOC information, and to apply for credit, please visit us at http://bit.ly/2QAudYX. CME/MOC credit will be available until December 26, 2019.
1. View abstract data
Please find an overview of your submitted data below; changes are no longer possible.
Abstract title
FUNCTION AND CLINICAL APPLICATION OF EMBRYONIC GENE
NANOG IN CANCER
Author
Lipscomb, Thomas H. , Yorktown High School, Yorktown Heights ,
United States of America
Co-author(s)
Zhang, L. M.D., Weill Medical College of Cornell Univ., New York City,
United States of America
Karajannis, M.A. M.D., Weill Medical College of Cornell Univ., New
York City, United States of America
Rafii, S. M.D., Weill Medical College of Cornell Univ., New York City,
United States of America
Jin, D.K. M.D. Ph.D., Weill Medical College of Cornell Univ., New York
City, United States of America
Topic 18. Acute myeloid leukemia - biology
Keywords Gene expression
Acute myeloid leukemia
Stem and progenitor cell
Gene therapy
Presentation
Preference
Poster presentation
Abstract text
BACKGROUND AND AIMS
Each year about 9,000 people die from acute myeloid leukemia (AML), a form of malignancy
affecting the hematopoietic stem cells in the bone marrow. The average age of a patient with AML
is 65 years old. Overall, the survival rate in adults under 65 is about 33%, but it is 4% for people
over 65. The division of normal cells is a regulated process, but when that regulation breaks down,
cells become cancerous and divide out of control. Only a few cancer cells have the ability to
replicate indefinitely. They are called cancer stem cells, and they are responsible for cancer’s long-
term growth and possibly metastasis. The embryonic gene Nanog is responsible for maintaining
the embryonic stem cells (ESCs) in an immature state to maintain their self-renewal capability and
2. allow long-term proliferation. Our aim was to determine if decreasing Nanog expression could
decrease proliferation in HL60 cancer cells as it does in embryonic stem cells.
METHODS AND RESULTS
Polymerase Chain Reaction (PCR) shows that Nanog is expressed in an AML cell line HL60,
SA726 AML cells primary human AML cells, and circulating mononuclear cells from a patient
diagnosed with glioblastoma, the deadliest and most common type of brain cancer. Nanog
expression did not decrease when the SA726 AML cells were subjected to all-trans retinoic acid
differentiation factor for a week. Trypan blue staining shows that cell proliferation decreased when
HL60 was subjected to 25 micromolars of sodium orthovanadate. Real-time PCR suggests a
decrease in Nanog expression after HL60 AML cells were subjected to 25 micromolars of sodium
orthovanadate for 72 hours.
Nanog and other embryonic genes may be highly specific cancer molecular biomarkers for new
diagnosis and therapeutic targets. Possible cancer treatments in the future may target Nanog and
its signaling pathways using small molecule inhibitors or gene-based therapy by delivering
shRNAi- or Zinc Finger Nuclease-plasmids to target cancer stem cells.
Also, two suspended blastocyst-like clusters (Figure 1) were found on day 7 of SA726 AML cell
culture on Mouse Embryonic Fibroblast feeder cells in Minimum Essential Medium 10% Fetal
Calf Serum. These are indicative of embryonic behavior of the cancer cells.
Suspended blastocyst-like SA726 AML cell clusters
CONCLUSION
These preliminary results suggest that a decrease in the cancer cell population happens
concurrently with a decrease in Nanog expression. This may justify a future study to investigate a
possible causal relationship.